Intralesional Chemotherapy (IC): Cisplatin + Epinephrine

Exclusion Criteria

• •1. Inability to tolerate awake, unsedated laryngeal procedures. Participants may opt to receive pre-procedure diazepam.
• •2. Participant unable to receive contrast.
• •3. Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor embolization).
• •4. Receipt of anticancer medications or investigational drugs within the following intervals before the date of the first dose of trial intervention:
• •1. \< 10 weeks from completion of any radio- or toxin-immunoconjugates.
• •2. \< 4 weeks for immunotherapy.
• •3. \< 3 weeks for radiotherapy.
• •4. \< 2 weeks for any investigational agent or other anticancer medications.
• •5. Steroids that are used for treatment of allergy or other underlying condition are permittable but not steroids started to treat cancer. Individuals receiving corticosteroids must be at a dose level ≤ 10 mg/day within 7 days of the trial intervention administration.
• •5. Inadequate recovery from toxicity and/or complications from a major surgery before starting therapy.
• •6. Current or previous other malignancy within 3 years of trial entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy.
• •7. Significant concurrent, uncontrolled medical condition, including, but not limited to, renal, hepatic, hematological, gastrointestinal (GI), endocrine, pulmonary, neurological, cerebral, or psychiatric disease.
• •8. Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment or exposure to a live vaccine within 30 days of dosing.
• •9. Known human immunodeficiency virus (HIV) infection or positivity on immunoassay. Note: HIV screening test is optional.
• •10. Current New York Heart Association Class II to IV congestive heart failure.
• •11. Uncontrolled or symptomatic arrhythmia or stroke in last 6 months, liver cirrhosis, or autoimmune disorder requiring immunosuppression or long-term corticosteroids (\> 10 mg daily prednisone equivalent).
• •12. Currently pregnant or breastfeeding.
• •13. Any condition that would, in the Investigator's judgment, interfere with full participation in the trial, including administration of trial intervention and attending required trial visits; pose a significant risk to the patient; or interfere with interpretation of trial data.
• •14. Patients with impaired decision-making capacity.